Out of all the types of breast cancer, triple negative remains one of the most difficult to treat. The illness does not respond to standard hormone therapy or methods that target the usual breast cancer receptors.
However, it looks like some progress is being made in the fight against this debilitating disease. According to UPI.com
, researchers at Northwestern University are showing promising results with a drug known to treat blood cancers.
"The anti-tumor effects of the arsenic nanobins against clinically aggressive triple negative breast tumors in mice are extremely encouraging," Vince Cryn, study co-senior author, said in a statement. "There's an urgent need to develop new therapies for poor prognosis triple negative breast cancer."
The drug works by specifically traveling to the tumor blood vessels and killing off the cells.
While triple negative breast cancer is rare, it remains an important issue for the minority community. According to BreastCancer.org, African-American and Hispanic women have the highest risk of developing the disease. The illness also affects the younger population, with most women being diagnosed before they turn 60 years old.